Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGINTERVENTIONAL

Artificial Intelligence Guided Patient Selection for Atrial Fibrillation Catheter Ablation: Randomized Clinical Trial (AI-PAFA Trial)

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Atrial fibrillation (AF) is a major cardiovascular disease with a prevalence of 1.7% of the total population in Korea, associated with 25% of ischemic stroke and 30% of heart failure, and is a major cardiovascular disease that doubles the risk of dementia. AF catheter ablation (AFCA) is an effective procedure that lowers the risk of heart failure mortality and cerebral infarction and improves cognitive or renal functions. However, the recurrence rate after the procedure is relatively high, especially in patients with long-standing persistent AF in which atrial remodeling has already progressed. Research on the prediction of treatment efficacy using artificial intelligence (AI) is being actively conducted around the world. We predicted the AFCA poor responders who will progress to permanent AF despite AFCA among a total of 3,372 patients included in the Yonsei AF Ablation cohort and the 2nd independent cohort with a long-term follow-up through AI with area under curve (AUC) 0.943. Therefore, in this prospective randomized clinical study, the difference between the patient selection for AFCA using AI algorithm and the clinical guidelines-based decision will be compared and evaluated in terms of long-term rhythm outcome.

Who May Be Eligible (Plain English)

Who May Qualify: 1. Left atrium size \< 55 mm 2. AF recurred during the administration of antiarrhythmic drugs or that antiarrhythmic drugs intolerable patients 3. Patients eligible for anticoagulant therapy (to prevent thromboembolic events) Who Should NOT Join This Trial: 1. AF associated with severe cardiac anomalies or structural heart disease with hemodynamic influence 2. Patients who have difficulty in CT imaging using a contrast medium 3. Patients with active internal bleeding 4. Inappropriate anticoagulant therapy 5. Serious comorbidities 6. Patients expected to survive less than 1 year 7. People with drug or alcohol addiction 8. Those who cannot read the consent form (illiterate, foreigners, etc.) 9. Patients who are judged unsuitable for participation in clinical research by the judgment of other investigators Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: 1. Left atrium size \< 55 mm 2. AF recurred during the administration of antiarrhythmic drugs or that antiarrhythmic drugs intolerable patients 3. Patients eligible for anticoagulant therapy (to prevent thromboembolic events) Exclusion Criteria: 1. AF associated with severe cardiac anomalies or structural heart disease with hemodynamic influence 2. Patients who have difficulty in CT imaging using a contrast medium 3. Patients with active internal bleeding 4. Inappropriate anticoagulant therapy 5. Serious comorbidities 6. Patients expected to survive less than 1 year 7. People with drug or alcohol addiction 8. Those who cannot read the consent form (illiterate, foreigners, etc.) 9. Patients who are judged unsuitable for participation in clinical research by the judgment of other investigators

Treatments Being Tested

PROCEDURE

Artificial Intelligence-based atrial fibrillation catheter ablation

1. Patient selection for Atrial Fibrillation Catheter Ablation(AFCA) 2. AI-guided prediction for poor responder of AFCA in the outpatient clinic 3. Sharing information on the AI prediction with the patient and family member 4. AFCA after consent to the procedure 5. Pulmonary vein isolation and additional treatment for non-pulmonary vein triggers 6. Monitoring esophageal temperature 7. Evaluation of Procedure and ablation time, and complication afer procedure 8. Post-procedure rhythm follow-up is carried out according to the study design above.

PROCEDURE

Medical Therapy

1. Patient selection for Atrial Fibrillation Catheter Ablation(AFCA) 2. Decision for AFCA based on clinical guidelines and the experience of the attending physician 3. AFCA after consent to the procedure 4. Pulmonary vein isolation and additional treatment for non-pulmonary vein triggers 5. Monitoring esophageal temperature 6. Evaluation of Procedure and ablation time, and complication afer procedure

Locations (1)

Severance Hospital, Yonsei University Health System
Seoul, South Korea